A proprietary extended-release oral minoxidil tablet induced rapid, robust and consistent hair growth in women with female pattern hair loss, according to topline results. Results from study 207 showed VDPHL01 (Veradermics) increased hair count for women who received once or twice daily dosing for 6 months and was generally well tolerated with no evidence of serious adverse events, including

Veradermics' oral VDPHL01 shows first efficacy data in women, boosting hair count 22.7 hairs/cm² at 6 months; Phase 2/3 trial due 2027.

Veradermics reported positive phase 2 data for VDPHL01, showing hair growth and favorable safety in women with pattern hair loss.